**TELA Bio, Inc. Reports Fiscal Year 2025 Results**
TELA Bio, Inc., a medical technology company focused on soft-tissue reconstruction solutions, announced its financial results for the fiscal year ended December 31, 2025. The company reported revenue of $80.3 million, an increase of 16% compared to $69.3 million in revenue for the year ended December 31, 2024. This growth was primarily driven by the addition of new customers, growing international sales, and the U.S. launch of the new larger-sized PRS configuration, partially offset by a decrease in average selling prices for hernia products due to product mix. The company sold 22,063 units of OviTex and 5,189 units of OviTex PRS during the year ended December 31, 2025, representing increases of 22% and 12%, respectively, in unit sales volume compared to the prior year.
The company's net loss for the year ended December 31, 2025, was $38.8 million, an increase of 3% compared to a net loss of $37.8 million for the year ended December 31, 2024. This includes a gain recognized of $7.6 million on the sale of NIVIS to the MiMedx Group, Inc for the year ended December 31, 2024. As of December 31, 2025, the company had an accumulated deficit of $397.6 million. Gross margin increased to 68% for the year ended December 31, 2025 from 67% for the year ended December 31, 2024, primarily due to lower expense recognized for excess and obsolete inventory adjustments as a percentage of revenue.
Key operational developments during the year included the launch of OviTex IHR in the U.S. and European markets, and the U.S. launch of larger sizes of OviTex PRS. The company also received FDA approval for its investigational device exemption application relating to the study of the safety and effectiveness of its OviTex PRS product in implant-based breast reconstruction. Sales and marketing expenses decreased by 2% to $63.2 million, while general and administrative expenses increased by 7% to $15.7 million. Research and development expenses increased by 5% to $9.2 million.
Looking ahead, TELA Bio intends to continue expanding its product offerings and treatment capabilities within soft-tissue reconstruction. The company plans to focus on enhanced surgical handling, larger product configurations, increased permeability, and longer-acting resorbable polymers. As of December 31, 2025, TELA Bio had cash and cash equivalents of $50.8 million. The company believes that its existing cash resources will be sufficient to meet its capital requirements and fund its operations for at least the next 12 months.
About TELA Bio, Inc.
TELA Bio, Inc. develops innovative soft-tissue reconstruction solutions, primarily through its OviTex portfolio, which combines biologic matrices with polymer reinforcement for hernia repair and plastic surgery. Its products aim to improve clinical outcomes, reduce complications, and lower costs. The company partners with healthcare providers, leverages extensive clinical data, and holds proprietary IP to address unmet needs in tissue repair markets worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.